<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antiserum was generated in rabbits to the RPMI 8226 tissue culture line of human <z:mp ids='MP_0009440'>myeloma</z:mp> cells, and its reactions with fixed smears of bone marrow aspirates from patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">macroglobulinemia</z:e>, <z:e sem="disease" ids="C0026470" disease_type="Disease or Syndrome" abbrv="">benign monoclonal gammopathy</z:e> (BMG), <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and nonneoplastic plasmacyosis was assessed by indirect immunofluorescence </plain></SENT>
<SENT sid="1" pm="."><plain>After absorption with preparations of bone marrow from <z:mpath ids='MPATH_458'>normal</z:mpath> individuals, the antiserum reacted to a significantly higher titer with a specific subpopulation of plasma cells in smears from 81% of patients having <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and 50% of patients having BMG than with cells in smears of bone marrow aspirates from <z:mpath ids='MPATH_458'>normal</z:mpath> individuals or patients having <z:hpo ids='HP_0001909'>leukemia</z:hpo> or nonneoplastic <z:e sem="disease" ids="C0085663" disease_type="Disease or Syndrome" abbrv="">plasmacytosis</z:e>, or than with cells in smears of peripheral blood from patients having Hodgkin's and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Absorption of the antiserum with RPMI 8226 cells or with a bone marrow preparation from a patient with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> but not the Jijoye line of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> reduced reactivity for cells in <z:mp ids='MP_0009440'>myeloma</z:mp> bone marrow </plain></SENT>
<SENT sid="3" pm="."><plain>The antiserum reacted at a lower titer with the Jijoye and EB-3 lines of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the RPMI 4098 cell line of <z:mpath ids='MPATH_458'>normal</z:mpath> human lymphocytes, and culture lines of human <z:hpo ids='HP_0002861'>melanoma</z:hpo> and <z:hpo ids='HP_0002669'>osteogenic sarcoma</z:hpo> than with the RPMI 8226 cells or bone marrow from certain patients having <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Approximately 50% of the cells reactive with antiserum to RPMI 8226 cells in the bone marrow of patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> were not producing immunoglobulin, as assessed by double immunofluorescence assay </plain></SENT>
<SENT sid="5" pm="."><plain>The data suggested that a subpopulation of plasma cells in the bone marrow of patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> possesses a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated antigen </plain></SENT>
</text></document>